These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33674268)

  • 1. Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator.
    Surapaneni S; Yerramilli U; Bai A; Dalvie D; Brooks J; Wang X; Selkirk JV; Yan YG; Zhang P; Hargreaves R; Kumar G; Palmisano M; Tran JQ
    Drug Metab Dispos; 2021 May; 49(5):405-419. PubMed ID: 33674268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro assessment of the binding and functional responses of ozanimod and its plasma metabolites across human sphingosine 1-phosphate receptors.
    Selkirk JV; Yan YG; Ching N; Paget K; Hargreaves R
    Eur J Pharmacol; 2023 Feb; 941():175442. PubMed ID: 36470447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study.
    Tran JQ; Zhang P; Ghosh A; Liu L; Syto M; Wang X; Palmisano M
    Adv Ther; 2020 Oct; 37(10):4381-4395. PubMed ID: 32857315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5.
    Selkirk JV; Dines KC; Yan YG; Ching N; Dalvie D; Biswas S; Bortolato A; Schkeryantz JM; Lopez C; Ruiz I; Hargreaves R
    J Pharmacol Exp Ther; 2021 Dec; 379(3):386-399. PubMed ID: 34535564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent, in Healthy Subjects.
    Tran JQ; Zhang P; Walker S; Ghosh A; Syto M; Wang X; Harris S; Palmisano M
    Adv Ther; 2020 Dec; 37(12):4944-4958. PubMed ID: 33025342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation into MAO B-Mediated Formation of CC112273, a Major Circulating Metabolite of Ozanimod, in Humans and Preclinical Species: Stereospecific Oxidative Deamination of (
    Bai A; Shanmugasundaram V; Selkirk JV; Surapaneni S; Dalvie D
    Drug Metab Dispos; 2021 Aug; 49(8):601-609. PubMed ID: 34011531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concentration-QTc Modeling of Ozanimod's Major Active Metabolites in Adult Healthy Subjects.
    Briggs E; Chapel S; Zhang P; Palmisano M; Tran JQ
    CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):119-126. PubMed ID: 33314790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ozanimod: First Approval.
    Lamb YN
    Drugs; 2020 Jun; 80(8):841-848. PubMed ID: 32385738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator.
    Tran JQ; Hartung JP; Tompkins CA; Frohna PA
    Clin Pharmacol Drug Dev; 2018 Aug; 7(6):634-640. PubMed ID: 29125718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS.
    Harris S; Tran JQ; Southworth H; Spencer CM; Cree BAC; Zamvil SS
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32737072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
    Cohen JA; Comi G; Arnold DL; Bar-Or A; Selmaj KW; Steinman L; Havrdová EK; Cree BA; Montalbán X; Hartung HP; Huang V; Frohna P; Skolnick BE; Kappos L;
    Mult Scler; 2019 Aug; 25(9):1255-1262. PubMed ID: 30043658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis.
    Fronza M; Lorefice L; Frau J; Cocco E
    Drug Des Devel Ther; 2021; 15():1993-2004. PubMed ID: 34007159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ozanimod (Zeposia) for multiple sclerosis.
    Med Lett Drugs Ther; 2020 Aug; 62(1605):132-134. PubMed ID: 32970043
    [No Abstract]   [Full Text] [Related]  

  • 14. Ozanimod: A Review in Relapsing Forms of Multiple Sclerosis.
    Nie T; Syed YY
    CNS Drugs; 2024 Nov; 38(11):931-941. PubMed ID: 39368032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.
    Cohen JA; Comi G; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Huang V; Kappos L;
    Lancet Neurol; 2019 Nov; 18(11):1021-1033. PubMed ID: 31492652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial.
    Cohen JA; Arnold DL; Comi G; Bar-Or A; Gujrathi S; Hartung JP; Cravets M; Olson A; Frohna PA; Selmaj KW;
    Lancet Neurol; 2016 Apr; 15(4):373-81. PubMed ID: 26879276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.
    Feagan BG; Sandborn WJ; Danese S; Wolf DC; Liu WJ; Hua SY; Minton N; Olson A; D'Haens G
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):819-828. PubMed ID: 32553149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients' Preferences for Sphingosine-1-Phosphate Receptor Modulators in Multiple Sclerosis Based on Clinical Management Considerations: A Choice Experiment.
    Keenan A; Whichello C; Le HH; Kern DM; Fernandez GS; Turner V; Das A; Quaife M; Ross AP
    Patient; 2024 Nov; 17(6):685-696. PubMed ID: 38748388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the interactions of JAK inhibitor and S1P receptor modulator drugs with the human gut microbiome: Implications for colonic drug delivery and inflammatory bowel disease.
    Favaron A; Abdalla Y; McCoubrey LE; Nandiraju LP; Shorthouse D; Gaisford S; Basit AW; Orlu M
    Eur J Pharm Sci; 2024 Sep; 200():106845. PubMed ID: 38971433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absorption, distribution, metabolism, and excretion of cenerimod, a selective S1P
    Boof ML; van Lier JJ; English S; Fischer H; Ufer M; Dingemanse J
    Xenobiotica; 2020 Aug; 50(8):947-956. PubMed ID: 32105166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.